Joshua A. Salomon

Professor of Global Health
Global Health and Population
Harvard School of Public Health
Home page:
PubMed Publications

Joshua Salomon, Ph.D. is a Professor of Global Health in the Department of Global Health and Population. His research focuses on priority-setting in global health, within three main substantive areas: (1) measurement of population health status and health valuations; (2) modeling and forecasting health outcomes and disease burden; and (3) evaluation of the potential impact and cost-effectiveness of current and future health interventions. A major emphasis has been on development of new approaches to data collection and analysis of health measurements with a particular focus on developing-country settings and aging populations. Another major research area revolves around development and application of analytic tools for priority-setting in global health. The goal of this work is to combine techniques of simulation modeling with decision analysis to inform decisions on use of existing health interventions and priorities for developing new technologies. Salomon earned his Ph.D. in 2001 from Harvard University.

Joshua Salomon
Spring 1
Stephen Resch
Spring 2
This course features case studies in the application of health decision science to policymaking and program management at various levels of the health system. Both developed and developing country contexts will be covered. Topics include: [1] theoretical foundations of cost-effectiveness analysis (CEA); [2] controversies and limitations of CEA in practice; [3] design and implementation of tools and protocols for measurement and valuation of cost and benefit of health programs; [4] integration of evidence of economic value into strategic planning and resource allocation decisions, performance monitoring and program evaluation; [5] the role of evidence of economic value in the context of other stakeholder criteria and political motivations.

RDS 282 will not be offered for 2010-2011

Dynamic Modelling of New TB Diagnostic Strategies

Estimating the impact and cost effectiveness of the GeneXpert tuberculosis assay in low resource, high burden settings

Cost-Effectiveness, Affordability, and Uncertainty

Even countries eligible for GAVI support for new vaccines will have to consider financial sustainability in addition to cost effectiveness